NCT00659074

Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions

Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 24 mg ODT With That of GlaxoSmithKine's Zofran 24 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Par Pharmaceutical, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Single-dose cross over comparative bioavailability of Ondansetron 24 mg oDT and Zofran 24 mg ODT

Detailed description

To Compare the single-dose bioavailability of Kali's Ondansetron 24 mg ODT with that of GlaxoSmithKine's Zofran 24 mg ODT under fasting conditions

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Ondansetron	ODT, single-dose, fasting
DRUG	Zofran	ODT, single-dose, fasting

Timeline

• Start date: 2003-10-01
• Primary completion: 2004-01-01
• Completion: 2004-02-01
• First posted: 2008-04-16
• Last updated: 2008-04-16

Locations

1 site across 1 country: Canada